Individualized drug and dose: The clinical pharmacologist's calling or curse?

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 11, 2005, Pages 975-978

  Begg, E J ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Department of Medicine ^*  (New Zealand)

Author keywords

Aminoglycosides; Clinical pharmacologist; Drugs in milk; Individualized dosing; Pharmacogenetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CYTOCHROME P450 2D6; GENTAMICIN; HYDRALAZINE; PERHEXILINE; PROCAINAMIDE; SEROTONIN UPTAKE INHIBITOR;

ANGINA PECTORIS; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; AUSTRALIA AND NEW ZEALAND; BIOINFORMATICS; BREAST FEEDING; BREAST MILK; CAUCASIAN; CONCENTRATION RESPONSE; CONFERENCE PAPER; DOSE RESPONSE; DOSIMETRY; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG MILK LEVEL; DRUG SAFETY; GENOTYPE; HUMAN; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; INDIVIDUALIZATION; MEDICAL RESEARCH; MEDICAL SOCIETY; MEDICAL SPECIALIST; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; TOXIC HEPATITIS; TREATMENT DURATION; VALIDATION PROCESS;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CARDIOVASCULAR AGENTS; CYTOCHROME P-450 CYP2D6; DRUG MONITORING; GENOTYPE; HUMANS; LIVER; MILK, HUMAN; MODELS, BIOLOGICAL; PERHEXILINE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 33745203453     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04294.x     Document Type: Conference Paper

References (26)

1. Kennedy M Chinwah P Wade DN. A pharmacological method of measuring mouth caecal transit time in man. Br. J. Clin. Pharmacol. 1979 8 : 372 3.
2. Wilson JT. Drugs in Breast Milk. ADIS Press, Sydney. 1981.
3. Atkinson HC Begg EJ. Prediction of drug concentrations in human skim milk from plasma protein binding and acid-base characteristics. Br. J. Clin. Pharmacol. 1988 25 : 495 503.
4. Atkinson HC Begg EJ. Relationship between human milk lipid: Ultrafiltrate and octanol-water partition coefficients. J. Pharm. Sci. 1988 77 : 796 8.
5. Atkinson HC Begg EJ. Prediction of drug distribution into human milk from physicochemical characteristics. Clin. Pharmacokinet. 1990 18 : 151 67.
6. Begg EJ Atkinson HC Duffull SB. Prospective evaluation of a model for the prediction of milk: Plasma drug concentrations from physicochemical characteristics. Br. J. Clin. Pharmacol. 1992 33 : 501 6.
7. Begg EJ Atkinson HC. Modelling of the passage of drugs into milk. Pharmacol. Ther. 1993 59 : 301 10.
8. Agatonovic-Kustrin S Tucker IG Zecevic M Zivanovic LJ. Prediction of drug transfer into human milk from theoretically derived descriptors. Anal. Chim. Acta 2000 418 : 181 95.
9. Larsen LA Ito S Koren G. Prediction of milk/plasma concentration ratio of drugs. Ann. Pharmacother. 2003 37 : 1299 306.
10. Doogue MPD Gardiner SJ Begg EJ. Predicting the breast milk to plasma concentration ratio of drugs. Ann. Pharmacother. 2004 38 : 174 5.
11. Ilett KF Hackett LP. Prediction of milk/plasma concentration ratio of drugs Ann. Pharmacother. 2004 38 : 175 6.
12. Begg EJ Peddie BA Chambers ST Boswell DR. Comparison of gentamicin dosing regimens using an in-vitro model. J. Antimicrob. Chemother. 1992 29 : 427 33.
13. Daikos GL Jackson GG Lolans VT Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J. Infect. Dis. 1990 162 : 414 20.
14. Barclay ML Begg EJ Chambers ST. Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob. Agents Chemother. 1992 36 : 1951 7.
15. Barclay ML Begg RJ Chambers ST Thornley PE Pattemore PK Grimwood K. Adaptive resistance to tobramycin in Psuedomonas aeruginosa lung infection in cystic fibrosis. J. Antimicrob. Chemother. 1996 37 : 1155 64.
16. Nicolau DP Freeman CD Belliveau PP Nightingale CH Ross JW Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob. Agents Chemother. 1995 3 : 650 5.
17. Begg EJ Barclay ML Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br. J. Clin. Pharmacol. 1995 39 : 605 9.
18. Sawchuk RJ Zaske DE Cipolle RJ Wargin WA Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin. Pharmacol. Ther. 1977 21 : 362 9.
19. Duffull SB Kirkpatrick CMJ Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br. J. Clin. Pharmacol. 1997 43 : 125 35.
20. Moore RD Smith CR Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with Gram-negative bacteremia. J. Infect. Dis. 1984 149 : 443 8.
21. Krynetskiy EY Evans WE. Closing the gap between science and clinical practice: The thiopurine S-methyltransferase polymorphism moves forward. Pharmacogenetics 2004 14 : 395 6.
22. Price Evans DA Manley KA McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960 11 : 485 91.
23. Barclay ML Sawyers SM Begg EJ et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 2003 13 : 627 32.
24. Stedman CAM Begg EJ Kennedy MA Roberts R Wilkinson TJ. Cytochrome P450 2 D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum. Psychopharmacol. Clin. Exp. 2002 17 : 187 90.
25. Gardiner SJ Begg EJ. Genotyping for drug-metabolizing enzymes: Does the promise meet the reality? Pharmacogenomics 2004 5 : 1033 6.
26. Wald NJ Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003 326 : 1419 25.